Influence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A Case-Control Study in the Iranian Population
Archives of Iranian Medicine · 2023
DOI: 10.34172/aim.2023.40 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Archives of Iranian Medicine, 2023. Verfasst von Parisa Mashayekhi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Hauptthemen laut MEDLINE: COVID-19, Genetic Predisposition to Disease, HLA-A Antigens, HLA-B Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
As an emerging pandemic disease, COVID-19 encompasses a spectrum of clinical diagnoses, from the common cold to severe respiratory syndrome. Considering the shreds of evidence demonstrating the relationship between human leukocyte antigen (HLA) allele diversity and infectious disease susceptibility, this study was conducted to determine the association of HLA alleles with COVID-19 severity in Iranian subjects.
Methods
In this case-control study, a total of 200 unrelated individuals (consisting of 100 people with severe COVID-19 and an average age of 55.54 as the case group, and 100 patients with mild COVID-19 with an average age of 48.97 as the control group) were recruited, and HLA typing (Locus A, B, and DR) was performed using the Olerup sequence-specific oligonucleotide (SSO) HLA-typing kit.
Results
Our results showed that HLA-A*11 and HLA-DRB1*14 alleles were more frequently observed in severe COVID-19 cases, while HLA-B*52 was more common in mild cases, which was in agreement with some previous studies.
Conclusion
Our results confirmed the evidence for the association of HLA alleles with COVID-19 outcomes. We found that HLA-A*11 and HLA-DRB1*14 alleles may be susceptibility factors for severe COVID-19, while HLA-B*52 may be a protective factor. These findings provide new insight into the pathogenesis of COVID-19 and help patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
- Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Antimicrobial resistance Research Center, Institute Of Immunology And Infectious Disease, Iran University of Medical Sciences, Tehran, Iran.
- Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Parisa Mashayekhi, Mir Davood Omrani, Zeynab Yassin, Sara Sadat Aghabozorg Afjeh
Zitieren
APA
Mashayekhi, P., Omrani, M. D., Yassin, Z., Dehghanifard, A., Ashouri, L., Aghabozorg Afjeh, S. S., & Shabanzadeh, Z. (2023). Influence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A Case-Control Study in the Iranian Population. Archives of Iranian Medicine. https://doi.org/10.34172/aim.2023.40
Vancouver
Mashayekhi P, Omrani MD, Yassin Z, Dehghanifard A, Ashouri L, Aghabozorg Afjeh SS, et al. Influence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A Case-Control Study in the Iranian Population. Archives of Iranian Medicine. 2023. doi:10.34172/aim.2023.40
BibTeX
@article{Mashayekhi2023,
author = {Mashayekhi, Parisa and Omrani, Mir Davood and Yassin, Zeynab and Dehghanifard, Ali and Ashouri, Leila and Aghabozorg Afjeh, Sara Sadat and Shabanzadeh, Zahra},
title = {Influence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A Case-Control Study in the Iranian Population},
journal = {Archives of Iranian Medicine},
year = {2023},
doi = {10.34172/aim.2023.40}
}
EUVIMED